Predicting response to a HER dimerisation inhibitor based on low HER3 expression

Details for Australian Patent Application No. 2008223069 (hide)

Owner F. Hoffmann-La Roche AG GENENTECH, INC.

Inventors Moecks, Joachim; Lin, Chin-Yu; Birkner, Merrill; Amler, Lukas C.; Strauss, Andreas

Agent Griffith Hack

Pub. Number AU-A-2008223069

PCT Pub. Number WO2008/109440

Priority 60/912,053 16.04.07 US; 60/892,640 02.03.07 US; 61/029,748 19.02.08 US

Filing date 29 February 2008

Wipo publication date 12 September 2008

International Classifications

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

13 August 2009 PCT application entered the National Phase

  PCT publication WO2008/109440 Priority application(s): WO2008/109440

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008223091-Sustained release pellets comprising wax-like material

2008223066-Compositions comprising derivatives of 3 -phenylpyridazine for treating seizurerelated disorders